Cancer Pain Relief Starts With a Constipation Plan

An opioid prescription for cancer pain should prompt a second conversation before the patient leaves the pharmacy: what is the plan to prevent constipation? The American Society of Clinical Oncology (ASCO) recommends offering opioids for moderate to severe pain related to cancer or active treatment unless contraindicated, with monitoring and management of adverse effects throughout therapy. Constipation deserves attention from the first dose.^1,2

Opioids slow intestinal transit, and patients generally do not develop tolerance to this effect. Waiting for symptoms to become troublesome leaves a predictable treatment complication unaddressed.²

For pharmacists, a bowel plan is part of supporting analgesia. It gives patients clear instructions for prevention and establishes when to contact the oncology team.

Start Prevention With the Prescription

The National Cancer Institute’s cancer pain guidance recommends starting a scheduled stimulant laxative, such as senna, when opioid therapy begins. Adding a stool softener does not provide further benefit. Laxatives can be titrated toward an unforced bowel movement every 1 to 2 days, with the regimen individualized to the patient.²

Before recommending a product, ask about the patient’s usual bowel pattern and what has changed. Establishing the last bowel movement and whether passage involves hard stool or straining provides a baseline for follow-up. Review other contributors, including reduced fluid intake and constipating medicines.³

Counseling should distinguish scheduled prevention from rescue treatment. A patient who hears only “take a laxative if needed” may wait until discomfort is substantial. Written instructions can specify the starting regimen and explain whom to contact if it does not work.

Adjust to Bowel Function

The NCI recommends continuing a bowel regimen while opioids are used and adjusting laxatives according to bowel function rather than opioid dose alone. An opioid increase should therefore trigger a check-in about bowel symptoms, not an automatic assumption that the existing regimen remains adequate.³

If constipation persists, confirm what the patient actually took before labeling treatment ineffective. A medication listed in the chart may have been unaffordable, misunderstood, or stopped because of cramping. Asking directly can reveal a correctable problem.³

After obstruction and impaction have been excluded, options include polyethylene glycol or another appropriate laxative. Persistent symptoms also warrant evaluation for additional causes, such as hypercalcemia. Hydration and activity, when feasible, support management but should not replace the prescribed bowel regimen.²

Recognize When Escalation Requires Assessment

Worsening abdominal pain with distention or vomiting, particularly when the patient cannot pass gas or stool, requires urgent medical assessment for obstruction. Escalating OTC treatment without evaluating these symptoms can delay necessary care. Watery leakage does not exclude constipation; stool can pass around a fecal impaction.³

Rectal treatments also require caution during cancer care. Suppositories and enemas are generally avoided in patients with neutropenia or thrombocytopenia because rectal manipulation can cause infection or bleeding complications. Pharmacists should check the treatment context before recommending an OTC rectal product.^2,3

Consider Targeted Treatment When Laxatives Fall Short

Peripherally acting μ-opioid receptor antagonists address the opioid mechanism underlying constipation. Evidence includes a randomized trial of 133 patients with advanced illness whose constipation persisted despite laxative treatment. After the first dose, 48% receiving subcutaneous methylnaltrexone had laxation within 4 hours versus 15% receiving placebo (P < .001). The study supports targeted treatment in a selected population with established constipation; it does not replace routine prevention.⁴

Product selection requires attention to formulation and indication. Methylnaltrexone injection (Relistor; Salix Pharmaceuticals) is FDA-approved for opioid-induced constipation in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. Its tablet indication concerns chronic noncancer pain, including specified circumstances involving prior cancer or its treatment.⁵

Methylnaltrexone is contraindicated with known or suspected gastrointestinal obstruction or increased risk of recurrent obstruction. The labeling warns about gastrointestinal perforation in susceptible patients and requires dose adjustment for renal impairment. Pharmacists should also counsel about severe diarrhea and possible opioid withdrawal.⁵

Keep the Plan Connected to Pain Care

Follow-up should establish whether the patient is passing stool comfortably and can follow the regimen at home. Documenting the response gives the oncology team information it can use at the next opioid adjustment.

Patients should leave knowing that constipation is treatable and worth reporting early. Making bowel management an expected part of cancer pain care helps pharmacists address complications while supporting continued access to needed analgesia.

REFERENCES

1. Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain From cancer or cancer teatment: ASCO Guideline. J Clin Oncol. 2023;41(4):914-930. doi:10.1200/JCO.22.02198

2. PDQ Supportive and Palliative Care Editorial Board. Cancer pain (PDQ)—health professional version. National Cancer Institute. Updated April 24, 2025. Accessed October 23, 2026. https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq

3. PDQ Supportive and Palliative Care Editorial Board. Gastrointestinal complications (PDQ)—health professional version. National Cancer Institute. Updated April 3, 2025. Accessed October 23, 2026. ​​https://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq

4. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343. doi:10.1056/NEJMoa0707377

5. Relistor. Prescribing information. Salix Pharmaceuticals; 2024. Accessed October 23, 2026. relistor-pi.pdf